PublishedJuly 30, 2026 Categories PARI News Partner News Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
PublishedJune 10, 2026 Category Partner News Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
PublishedMay 12, 2026 Category Partner News Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001
PublishedApril 26, 2026 Category Partner News Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
PublishedApril 15, 2026 Categories eFlow Integrated PARI Publications A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser
